Literature DB >> 7738180

Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study.

M H Lafage1, R Balena, M A Battle, M Shea, J G Seedor, H Klein, W C Hayes, G A Rodan.   

Abstract

Fluoride stimulates trabecular bone formation, whereas bisphosphonates reduce bone resorption and turnover. Fracture prevention has not been convincingly demonstrated for either treatment so far. We compared the effects of 1-yr treatment of 9-mo-old minipigs with sodium fluoride (NaF, 2 mg/kg/d p.o.) or alendronate (ALN, 4 amino-1-hydroxybutylidene bisphosphonate monosodium, 1 mg/kg/d p.o.) on the biomechanical and histomorphometric properties of pig bones. As expected, NaF increased and ALN decreased bone turnover, but in these normal animals neither changed mean bone volume. NaF reduced the strength of cancellous bone from the L4 vertebra, relative to control animals, and the stiffness (resistance to deformation) of the femora, relative to the ALN group. In the ALN-treated animals, there was a strong positive correlation between bone strength and L5 cancellous bone volume, but no such correlation was observed in the NaF group. Furthermore, the modulus (resistance to deformation of the tissue) was inversely related to NaF content and there was a relative decrease in bone strength above 0.25 mg NaF/g bone. Moreover, within the range of changes measured in this study, there was an inverse correlation between bone turnover, estimated as the percentage of osteoid surface, and modulus. These findings have relevant implications regarding the use of these agents for osteoporosis therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738180      PMCID: PMC295812          DOI: 10.1172/JCI117901

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Dose effects on ewe bone remodeling of short-term sodium fluoride administration--a histomorphometric and biochemical study.

Authors:  P Chavassieux; P Pastoureau; G Boivin; M C Chapuy; P D Delmas; P J Meunier
Journal:  Bone       Date:  1991       Impact factor: 4.398

Review 2.  Mechanical loading, estrogen deficiency, and the coupling of bone formation to bone resorption.

Authors:  G A Rodan
Journal:  J Bone Miner Res       Date:  1991-06       Impact factor: 6.741

3.  Fluoride and bone--quantity versus quality.

Authors:  R Lindsay
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

Review 4.  Effects of fluoride treatment on bone strength.

Authors:  D R Carter; G S Beaupré
Journal:  J Bone Miner Res       Date:  1990-03       Impact factor: 6.741

5.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Authors:  M Sato; W Grasser; N Endo; R Akins; H Simmons; D D Thompson; E Golub; G A Rodan
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

6.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

7.  Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis.

Authors:  M Passeri; M C Baroni; M Pedrazzoni; G Pioli; M Barbagallo; D Costi; M Biondi; G Girasole; B Arlunno; E Palummeri
Journal:  Bone Miner       Date:  1991-12

8.  The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats.

Authors:  J G Seedor; H A Quartuccio; D D Thompson
Journal:  J Bone Miner Res       Date:  1991-04       Impact factor: 6.741

9.  Abnormal bone mineralization after fluoride treatment in osteoporosis: a small-angle x-ray-scattering study.

Authors:  P Fratzl; P Roschger; J Eschberger; B Abendroth; K Klaushofer
Journal:  J Bone Miner Res       Date:  1994-10       Impact factor: 6.741

10.  Effects of fluoride on cortical bone remodeling in the growing domestic pig.

Authors:  J Kragstrup; A Richards; O Fejerskov
Journal:  Bone       Date:  1989       Impact factor: 4.398

View more
  18 in total

Review 1.  The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.

Authors:  Matthew R Allen
Journal:  Odontology       Date:  2011-01-27       Impact factor: 2.634

2.  Assessment of fluoride-induced changes on physicochemical and structural properties of bone and the impact of calcium on its control in rabbits.

Authors:  Subarayan Bothi Gopalakrishnan; Gopalan Viswanathan
Journal:  J Bone Miner Metab       Date:  2011-09-27       Impact factor: 2.626

Review 3.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 4.  A biomechanical perspective on bone quality.

Authors:  C J Hernandez; T M Keaveny
Journal:  Bone       Date:  2006-07-28       Impact factor: 4.398

Review 5.  Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss.

Authors:  Mone Zaidi; Charles H Turner; Ernesto Canalis; Roberto Pacifici; Li Sun; Jameel Iqbal; X Edward Guo; Stuart Silverman; Solomon Epstein; Clifford J Rosen
Journal:  Curr Osteoporos Rep       Date:  2009-12       Impact factor: 5.096

Review 6.  Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence.

Authors:  Uri A Liberman
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

7.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

Authors:  P M Chavassieux; M E Arlot; C Reda; L Wei; A J Yates; P J Meunier
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

8.  Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.

Authors:  Jean-Yves Reginster; Eric Abadie; Pierre Delmas; René Rizzoli; Willard Dere; Philippevan der Auwera; Bernard Avouac; Maria-Luisa Brandi; Anastasia Daifotis; Adolfo Diez-Perez; Gonzalo Calvo; Olof Johnell; Jean-Marc Kaufman; Gottfried Kreutz; Andrea Laslop; Fritz Lekkerkerker; Bruce Mitlak; Per Nilsson; John Orloff; Mary Smillie; Andrew Taylor; Yannis Tsouderos; Dominique Ethgen; Bruno Flamion
Journal:  Osteoporos Int       Date:  2005-08-10       Impact factor: 4.507

9.  Modulation of bone turnover by alfacalcidol and/or alendronate does not prevent glucocorticoid-induced osteoporosis in growing minipigs.

Authors:  Shojiro Akahoshi; Akinori Sakai; Shinobu Arita; Satoshi Ikeda; Yoshiomi Morishita; Hideki Tsutsumi; Masako Ito; Ayako Shiraishi; Toshitaka Nakamura
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

Review 10.  A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.

Authors:  J P Devogelaer
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.